Item 5. Other Information

2K characters. Original on sec.gov · Markdown

Item 5. Other Information

Rule 10b5-1 Trading Plans

Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the third quarter of 2023, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).


Name and Title	Date of Adoption of Trading Plan	Scheduled Expiration Date of Trading Plan (1)	Maximum Shares Subject to Trading Plan
E. Morrow “Morrey” Atkinson III EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations	8/22/2023	4/30/2024	9,224(2)
Reshma Kewalramani President, Chief Executive Officer and Director	8/11/2023	8/15/2024	27,330
Jeffrey M. Leiden Executive Chairman	8/4/2023	5/15/2025	40,454(2)
Bastiano Sanna EVP, Chief of Cell and Genetic Therapies	8/25/2023	8/9/2024	32,833(2)
Charles F. Wagner, Jr. EVP, Chief Financial Officer	8/18/2023	8/9/2024	6,000
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan. (2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.

Previous: Item 1A. Risk Factors · Next: Item 6. Exhibits